{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:28:36Z","timestamp":1790008116084,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.annder.2007.12.006","type":"journal-article","created":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T07:45:06Z","timestamp":1203061506000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Effets secondaires cutan\u00e9s du sorafenib et du sunitinib"],"prefix":"10.1016","volume":"135","author":[{"given":"J.","family":"Autier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2007.12.006_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0151-9638(06)71093-6","article-title":"Aspects cliniques et prise en charge des effets secondaires cutan\u00e9s des inhibiteurs du r\u00e9cepteur \u00e0 l\u2019EGF","volume":"133","author":"Guillot","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2007.12.006_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2007.12.006_bib3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(06)69489-0","article-title":"Sunitinib for imatinib-resistant GIST","volume":"368","author":"Joensuu","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2007.12.006_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2007.12.006_bib5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2007.12.006_bib6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacocinetic study of the novel Raf kinase vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2007.12.006_bib7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2007.12.006_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitargeted tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2007.12.006_bib9","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v 3.0. http:\/\/ctep.cancer.gov\/reporting\/ctc.html."},{"key":"10.1016\/j.annder.2007.12.006_bib10","first-page":"240","article-title":"Splinter haemorrhages: facts and fiction","volume":"22","author":"Young","year":"1988","journal-title":"J R Coll Physicians Lond"},{"key":"10.1016\/j.annder.2007.12.006_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-143-4-200508160-00021","article-title":"Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?","volume":"143","author":"Robert","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2007.12.006_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2007.12.006_bib13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2230.2006.02223.x","article-title":"Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor","volume":"31","author":"Lacouture","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2007.12.006_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(03)12805-X","article-title":"Tyrosine kinase inhibition and grey hair","volume":"361","author":"Robert","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2007.12.006_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment: specific issues related to safety, fertility, and pregnancy","volume":"40","author":"Hensley","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.annder.2007.12.006_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI 571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2007.12.006_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1101\/gad.14.3.301","article-title":"c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi","volume":"14","author":"Wu","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.annder.2007.12.006_bib18","first-page":"71","article-title":"Le g\u00e8ne B-raf code pour de multiples isoformes ayant une activit\u00e9 Mek-1 kinase","volume":"189","author":"Papin","year":"1995","journal-title":"C R Seances Soc Biol Fil"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963807000488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963807000488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:53:32Z","timestamp":1758970412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963807000488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0151963807000488"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2007.12.006","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets secondaires cutan\u00e9s du sorafenib et du sunitinib","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2007.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}